Cytokinetics (CYTK) Reports In-Line Q3 EPS
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Price: $75.87 +2.35%
Financial Fact:
License revenues from related parties: 53.03M
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
License revenues from related parties: 53.03M
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Cytokinetics (NASDAQ: CYTK) reported Q3 EPS of ($0.51), in-line with the analyst estimate of ($0.51). Revenue for the quarter came in at $6.22 million versus the consensus estimate of $5.19 million.
For earnings history and earnings-related data on Cytokinetics (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
- Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance
- HSBC Upgrades Blue Star Limited (BLSTR:IN) to Buy
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
